BioCentury
ARTICLE | Clinical News

PEP005 topical ingenol mebutate gel: Phase III data

May 25, 2009 7:00 AM UTC

In the double-blind, Australian and U.S. Phase III REGION-I trial in 255 patients with AK lesions on non-head locations, 0.05% PEP005 Gel applied once daily for 2 consecutive days met the primary endp...